You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, November 2015
|
| DOI | 10.1186/2051-1426-3-s2-p171 |
| Authors |
Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, Enriqueta Felip, Patrick Forde, Marina Garassino, Sarah Goldberg, Johan Vansteenkiste, Anthony Jarkowski, Stuart McIntosh, Luping Zhao, Scott Antonia |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 22 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 17% |
| Researcher | 4 | 17% |
| Student > Ph. D. Student | 3 | 13% |
| Student > Doctoral Student | 2 | 9% |
| Student > Bachelor | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Agricultural and Biological Sciences | 2 | 9% |
| Psychology | 1 | 4% |
| Sports and Recreations | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 6 | 26% |